Interferon beta-1a in primary progressive multiple sclerosis

Journal of the Neurological Sciences

Volumn 206, Issue 2, 2003, Pages 215-216

  Leary, Siobhan M ^a   Thompson, Alan J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Interferon beta 1a; Primary progressive multiple sclerosis; Therapeutics

Indexed keywords

BETA1A INTERFERON; LIVER ENZYME;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FLU LIKE SYNDROME; HUMAN; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT;

EID: 0037441441     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00350-7     Document Type: Article

References (11)

1. Thompson A.J., Polman C.H., Miller D.H.et al. Primary progressive multiple sclerosis. Brain. 120:1997;1085-1096.
2. Double-masked trial of azathioprine in multiple sclerosis. Lancet. ii:1988;179-183.
3. Goodkin D.E., Rudick R.A., VanderBrug Medendorp S.et al. Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann. Neurol. 37:1995;30-40.
4. Rice G.P.A.et al. Cladribine and progressive MS. Clinical and MRI outcomes of a multicenter controlled trial. Neurology. 54:2000;1145-1155.
5. Poehlau D., Federlein J., Postert T.et al. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult. Scler. 3:1997;149-152.
6. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ. Interferon β-1a in primary progressive MS: an exploratory randomized controlled trial. Neurology [in press].
7. Montalban X., Tintore M., Rio J.et al. Primary progressive multiple sclerosis: description of 121 patients and study design of a controlled trial. Mult. Scler. 4:1998;344. [abstract].
8. Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler. [in press].
9. Kita M., Goodkin D.E., Bacchetti P.et al. A phase II trial of mitoxantrone in patients with primary progressive multiple sclerosis. Neurology. 54(Suppl. 3):2000;A22. [abstract].
10. Wolinsky J.S., Narayana P.A. Characteristics at entry into the glatiramer acetate study of primary progressive multiple sclerosis: the PROMiSe trial. J. Neurol. 248(Suppl. 2):2001;134. [abstract].
11. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology. 33:1983;1444-1452.